Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats.
Epigallocatechin gallate (EGCG) reportedly enhances plasma adiponectin levels in models of insulin resistance and obesity. In this study, we found that EGCG increases plasma adiponectin levels and decreases plasma triacylglycerol levels in non-obese diabetic Goto-Kakizaki rats with insulin secretory dysfunction. These results suggest that EGCG ameliorates lipid metabolic abnormality even in non-obese rats, probably by increasing adiponectin production.
Shimada
Masaya
M
Laboratory of Nutritional Physiology, Graduate School of Nutritional and Environmental Sciences, COE Program for 21st Century, University of Shizuoka, Shizuoka, Japan.
Mochizuki
Kazuki
K
Sakurai
Naoko
N
Goda
Toshinao
T
D052242:Adiponectin / Q000097:blood*; D000818:Animals; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D019587:Dietary Supplements; D050356:Lipid Metabolism / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
D052242:Adiponectin; D014280:Triglycerides; D002392:Catechin; C045651:epigallocatechin gallate